Principle Investigator for the clinical trials

2018/2019 : GS-US- 419-3895 (DIVERSITY1) : Combined Phase 3, Double blind, Randomized, Placebo controlled studies evaluating the Efficacy and Safety of Filgotinib in the induction and maintenance of remission in Moderately to severely active Crohns disease

2018/ 2019: GS – US- 419-3896 (DIVERSITY LTE): A long term extension study to evaluate safety of Filgotinib in subjects with Crohns disease2018/2019: GS-US-418-3898 (SELECTION1): Combined Phase2b/ 3, Double blind, Randomized, Placebo controlled studies evaluating the Efficacy and Safety of Filgotinib in the induction and maintenance of remission in Moderately to severely active Ulcerative colitis

2018/2019: GS-US-418-3898 (SELECTION1): Combined Phase2b/ 3, Double blind, Randomized, Placebo controlled studies evaluating the Efficacy and Safety of Filgotinib in the induction and maintenance of remission in Moderately to severely active Ulcerative colitis

2018/2019: GS-US-418-3899 (SELECTION LTE): A long term extension study to evaluate safety of Filgotinib in subjects with Ulcerative Colitis.